Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation

Area of Science:

• Hematology
• Coagulation Disorders
• Pharmacology

Background:

• Inherited factor VII (FVII) deficiency presents diverse clinical phenotypes.
• Management of bleeding episodes in FVII deficiency requires individualized approaches.

Purpose of the Study:

• To evaluate the efficacy and safety of different treatments for spontaneous and traumatic bleeding in patients with FVII deficiency.
• To analyze treatment outcomes based on bleed type and patient characteristics.

Main Methods:

• Retrospective analysis of 101 bleeding episodes in 75 patients with FVII deficiency from the Seven Treatment Evaluation Registry (STER).
• Bleeding episodes were categorized by type (e.g., haemarthroses, CNS, GI, menorrhagia).
• Treatments evaluated included recombinant activated FVII (rFVIIa), fresh frozen plasma (FFP), plasma-derived FVII (pdFVII), and prothrombin-complex concentrates.

Main Results:

• Recombinant activated FVII (rFVIIa) was the most frequently used treatment (76 episodes) and demonstrated high success rates for haemarthroses, muscle haematomas, epistaxis, and gum bleeding with one-day therapy.
• Favorable outcomes were observed for menorrhagia with single or multiple rFVIIa doses.
• No thrombotic events were reported; two patients developed inhibitors after repeated treatment (one with rFVIIa, one with pdFVII).

Conclusions:

• Single intermediate doses of rFVIIa (median 60 µg/kg) are effective for most bleeding episodes in FVII deficiency.
• Short- or long-term prophylaxis may be optimal for severe bleeds, such as central nervous system (CNS) and gastrointestinal (GI) hemorrhages.
• Treatment strategies should be tailored to the specific bleeding phenotype in FVII deficiency.